Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Annexin A11
(Anxa11) is associated with various cancers. Using a pair of syngeneic murine hepatocarcinoma cells, Hca-P with ~25% and Hca-F with ~75% lymph node metastatic (LNM) potentials, we demonstrated Anxa11 involvement in hepatocarcinoma lymphatic metastasis. Here,
ANXA11
acted as a suppressor for the tumorigenicity, LNM and 5-FU resistance of Hca-P via
c-Jun
. We constructed monoclonal Hca-P cell line with stable
ANXA11
knockdown. Although Bax and Bcl-2 levels increased in shRNA-Anxa11-transfected Hca-P,
ANXA11
downregulation showed no clear effect on Hca-P apoptosis.
ANXA11
downregulation promoted in vitro migration and invasion capacities of Hca-P. In situ adhesion potential of Hca-P cells toward LN was significantly enhanced following
ANXA11
downregulation. Consistently,
ANXA11
downregulation promoted the in vivo tumor growth and LNM capacities of Hca-P cells.
ANXA11
knockdown enhanced the chemoresistance of Hca-P cells specifically toward 5-FU instead of cisplatin. Its downregulation increased
c-Jun
(pSer73) and decreased
c-Jun
(pSer243) levels in Hca-P.
c-Jun
(pSer243) downregulation seemed to be only correlated with
ANXA11
knockdown without the connection to 5-FU treatment. Interestingly, compared with scramble-Hca-P cells, the levels of
c-Jun
and
c-Jun
(pSer73) in shRNA-Anxa11-Hca-P cells were upregulated in the presences of 0.1 and 1.0 mg/L 5-FU. The levels changes from
c-Jun
and
c-Jun
(pSer73) in Hca-P cells showed a more obvious tendency with the combination of
ANXA11
knockdown and 5-FU treatment.
ANXA11
level regulates LNM and 5-FU resistance of Hca-P via
c-Jun
pathway. It might play an important role in hepatocarcinoma cell malignancy and be a therapeutic target for hepatocarcinoma.
...
PMID:ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun. 2690 48